Envista Holdings Reports Q4 2023 Non-GAAP EPS of $0.52, Beating Expectations by $0.03
February 10, 2023
Trending News 🌧️
Envista Holdings ($NYSE:NVST) (ENVA) reported Q4 2023 non-GAAP earnings per share of $0.52, beating analyst expectations by $0.03. Envista Holdings is an American company that provides medical devices and technologies for diagnostic imaging, patient monitoring and diagnostics, and information management. The company’s top-line growth was driven by increased demand for its products in the U.S., Japan, and Europe. This improvement was due to better pricing on its products and better cost management. Envista also saw favorable currency exchange rates, which had a positive impact on its bottom line.
This improvement was driven by strong revenue growth, better pricing and cost management, and favorable exchange rates. Envista’s strong performance in Q4 2023 is a testament to its ability to execute its strategy and deliver on its growth objectives. The company is well-positioned to continue to capitalize on its growth opportunities and drive shareholder returns going forward.
Price History
Envista’s fourth-quarter 2023 results marked a solid end to the year, as the company was able to beat expectations despite facing difficult market conditions due to the pandemic. Furthermore, Envista’s strong balance sheet and cash flow enabled it to repurchase shares at an attractive price, indicating the company’s confidence in its future outlook. Going forward, investors are keeping an eye on Envista as it looks to capitalize on its strong fundamentals and continue to deliver strong results in the upcoming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Envista Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 2.56k | 255.4 | 8.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Envista Holdings. More…
| Operations | Investing | Financing |
| 208.4 | -367.6 | 82.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Envista Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.41k | 2.45k | 24.28 |
Key Ratios Snapshot
Some of the financial key ratios for Envista Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.8% | 1.3% | 10.9% |
| FCF Margin | ROE | ROA |
| 5.5% | 4.4% | 2.7% |
Analysis
ENVISTA HOLDINGS presents an interesting opportunity for investors, but it is important to consider the risk involved. GoodWhale can help you analyze its financials and provide a Risk Rating score. Our data suggests that ENVISTA HOLDINGS is a high risk investment, and it is important to take into account both the financial and business aspects of this company. GoodWhale’s analysis detected two risk warnings in the balance sheet and cashflow statement. These warnings provide insight into the company’s financial standing and should be taken into consideration before investing. By registering with us, you can explore these warnings in more detail, as well as assess other key metrics such as liquidity, leverage and profitability. The Risk Rating score is only one piece of the puzzle – investors should also study the company’s fundamentals and look for opportunities to mitigate risk. This could include diversifying investments or investing in stable sectors. Ultimately, it is important to conduct thorough research before investing in ENVISTA HOLDINGS or any other company. More…
Peers
Its main competitors are Medikit Co Ltd, Nihon Kohden Corp, and Fukuda Denshi Co Ltd. Envista has a strong market presence in the US, Europe, and Asia Pacific.
– Medikit Co Ltd ($TSE:7749)
As of 2022, Medikit Co Ltd has a market cap of 41.17B and a Return on Equity of 6.14%. The company produces and sells medical equipment and supplies. It offers a wide range of products, including medical devices, pharmaceuticals, and over-the-counter drugs. Medikit also provides services, such as medical examinations and consultations.
– Nihon Kohden Corp ($TSE:6849)
Nihon Kohden is a Japanese manufacturer of medical equipment, with a particular focus on patient monitoring systems. The company has a market cap of 278.79B as of 2022 and a return on equity of 13.19%. Nihon Kohden has a long history, dating back to 1951, and has been a leading player in the medical equipment industry for many years. The company’s products are used in hospitals and clinics around the world, and it has a strong reputation for quality and reliability.
– Fukuda Denshi Co Ltd ($TSE:6960)
Fukuda Denshi Co Ltd is a Japanese company that manufactures and sells medical equipment. The company has a market cap of 138.83B as of 2022 and a Return on Equity of 9.95%. Fukuda Denshi is a leading manufacturer of medical equipment and supplies, and its products are used in hospitals and clinics around the world. The company’s products include medical imaging devices, patient monitors, and medical electronics.
Summary
Envista Holdings reported its financial results for the fourth quarter of 2023, posting a non-GAAP EPS of $0.52, exceeding analyst expectations by $0.03. This is a positive sign for investors, suggesting that the company is continuing to perform well. The company’s revenue and operating income also improved, providing further evidence of successful business operations.
In addition, Envista’s balance sheet remains strong, with sizable cash reserves and low debt. Overall, Envista Holdings offers attractive investment opportunities, given its solid financial performance and sound financial position.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
